Table 2.
The COVID-19-related data among MS patients in the Omicron era
| Variables | N (%) |
|---|---|
| History of COVID-19 in the Omicron era | |
| Yes | 76 (43.7%) |
| No | 98 (56.3%) |
| History of COVID-19 in the earlier waves of COVID-19 | |
| Yes | 72 (41.4%) |
| No | 102 (58.6%) |
| Time of COVID-19 after COVID-19 vaccination | |
| After 1st dose | 4 (5.4%) |
| After 2nd dose | 16 (21.62%) |
| After 3rd dose | 54 (72.97%) |
| The severity of COVID-19 | |
| Required hospitalization | 6 (6.97%) |
| Required home care | 63 (73.25%) |
| No treatment required | 17 (19.76%) |
| COVID-19 vaccination | |
| 0 | 3 (1.7%) |
| 1 | 5 (2.9%) |
| 2 | 31 (17.8%) |
| 3 | 133 (76.4%) |
| 4 | 2 (1.1%) |
| Relapse after receiving the COVID-19 vaccine | |
| Yes | 11 (6.43%) |
| No | 160 (93.57%) |
MS multiple sclerosis